Roferon-A

In the US, Roferon-A (interferon alfa-2a systemic) is a member of the drug class antineoplastic interferons and is used to treat Chronic Myelogenous Leukemia, Hairy Cell Leukemia, Hepatitis C, Kaposi's Sarcoma, Lymphoma and Renal Cell Carcinoma.

US matches:

• Roferon-A Solution


• Roferon-A

UK matches:

• Roferon-A 18MIU/0.6ml Cartridge (SPC)
• Roferon-A Pre-Filled Syringe (SPC)

Ingredient matches for Roferon-A

Interferon alfa

Interferon alfa Interferon alfa-2a (Lys-23; His-34) (a derivative of Interferon alfa) is reported as an ingredient of Roferon-A in the following countries:

• Argentina


• Armenia


• Aruba


• Australia


• Azerbaijan


• Bahrain


• Bangladesh


• Belgium


• Bolivia


• Bosnia & Herzegowina


• Botswana


• Brazil


• Bulgaria


• Cambodia


• Chile


• China


• Croatia (Hrvatska)


• Czech Republic


• Egypt


• Estonia


• Finland


• Georgia


• Germany


• Ghana


• Greece


• Hong Kong


• Hungary


• India


• Iran


• Iraq


• Ireland


• Israel


• Italy


• Jamaica


• Japan


• Jordan


• Kazakhstan


• Kenya


• Kuwait


• Kyrgyzstan


• Laos


• Lebanon


• Libya


• Lithuania


• Luxembourg


• Macedonia


• Malawi


• Malaysia


• Mexico


• Moldova


• Morocco


• Namibia


• Nepal


• Netherlands


• New Zealand


• Nigeria


• Oman


• Pakistan


• Peru


• Philippines


• Poland


• Portugal


• Qatar


• Romania


• Russian Federation


• Saudi Arabia


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• South Korea


• Spain


• Sri Lanka


• Sudan


• Sweden


• Switzerland


• Syria


• Taiwan


• Tanzania


• Thailand


• Trinidad & Tobago


• Turkey


• Turkmenistan


• Uganda


• Ukraine


• United Arab Emirates


• United Kingdom


• United States


• Uruguay


• Uzbekistan


• Venezuela


• Vietnam


• Yemen


• Zambia


• Zimbabwe

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.